fluorouracil and celecoxib

fluorouracil has been researched along with celecoxib in 66 studies

Research

Studies (66)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's38 (57.58)29.6817
2010's26 (39.39)24.3611
2020's2 (3.03)2.80

Authors

AuthorsStudies
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Ekins, S; Williams, AJ; Xu, JJ1
Bensdorf, K; Guo, C; Gust, R; Huang, W; Liu, H; Liu, W; Qian, H; Rubner, G; Wang, Y; Wellner, A; Zhang, H; Zhang, Y; Zhou, J1
Duan, YC; Lin, ZT; Liu, GZ; Liu, HM; Wang, P; Xu, HW; Zheng, JX1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Ji, Y; Ju, L; Lu, X; Wu, K; Yang, H; Yu, M1
Cai, H; Huang, X; Huang, Y; Jiang, B; Jiang, J; Shen, H; Sun, Y; Wu, X; Xu, J; Xu, S; Yao, H; Zhang, P1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF1
Akber Ansari, S; Arote, R; Chhajed, S; Pathan, SK; Patil, R; Sangshetti, J; Shinde, DB1
Abd El Wahab, SM; Alaaeddine, R; Allam, RM; Angeli, A; Belal, ASF; Daabees, H; Eid, AH; El-Hawash, SA; El-Yazbi, AF; Elagawany, M; Elzahhar, PA; Hegazy, RR; Helmy, MW; Supuran, CT1
Rich, T1
Ayers, GD; Lin, E; Morris, JS1
Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M1
Rich, TA; Shepard, R1
Fuchs, CS1
Breza, TS; Oberyszyn, TM; Tober, KL; Wilgus, TA1
Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E1
Berman, B; Ramirez, CC; Villa, AM1
Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C1
Blanke, CD; Deloughery, TG; Koop, DR; Mattek, NC1
Flinner, R; Forbes, A; Fuhrman, C; Gaffney, DK; Greven, K; Kerlin, K; Nichols, RC; Ryu, J; Winter, K; Zempolich, K1
Borsellino, N; Cartenì, G; Colucci, G; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Manzione, L; Paoletti, G; Pezzella, G; Romito, S1
Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J1
Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM1
Chow, LW; Loo, WT; Lui, EL; Toi, M; Wai, CC; Zhu, L1
Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR1
Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S1
Chow, LW; Toi, M; Ueno, T1
Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Mc Bride, WH; Roels, S1
André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C1
Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR1
Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K1
Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF1
El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM1
Egawa, S; Hayashi, N; Iijima, H; Irie, T; Ishii, S; Kakiuchi, Y; Kawano, S; Murata, H; Nishida, T; Shinzaki, S; Takehara, T; Tsuji, S; Tsujii, M; Yasumaru, M; Yoshio, T1
Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC1
Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K1
Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS1
Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C1
Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ1
Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S1
Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N1
Davies, JM; Goldberg, RM1
Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I1
Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X1
D'Hoore, A; Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Libbrecht, L; McBride, WH; Penninckx, F; Roels, S; Van Cutsem, E1
Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I1
Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK1
Foley, EF; Friel, CM; Koc, M; Moskaluk, CA; Rich, TA; Romney, DA; Unger, KR1
Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R1
Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX1
Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ1
Chan, AP; Chan, SK; Hasan, MR; Jin, C; Kim, J; Kim, YB; Le, ND; Rahman, M; Selvarajan, K; Tai, IT1
Chen, WC; Guo, Q; Zhang, DQ; Zhu, JH1
Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY1
Guo, HQ; Liu, YY; Yang, SJ; Yao, SN; Yao, ZH; Yuan, YD; Zhao, Y1
Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G1
Jia, Q; Sui, W; Wang, Z; Wu, L; Zhang, W; Zhang, Y1
Feng, YG; Gao, ZX; Li, YQ; Liu, WD; Shi, LH; Sun, XE; Sun, XN; Zhang, HM; Zhang, XQ1
Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW1
Gotoh, N; Igarashi, K; Karasawa, T; Kato, Y; Kuzumaki, N; Narita, M; Otsuka, M; Sagara, A1
Baez-Diaz, L; Bandos, H; Brufsky, AM; Carolla, RL; Fehrenbacher, L; Geyer, CE; Hamm, JT; Jacobs, SA; Julian, TB; Mamounas, EP; Paterson, AHG; Polikoff, J; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Ward, PJ; Wolmark, N1

Reviews

8 review(s) available for fluorouracil and celecoxib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Recently reported biological activities of pyrazole compounds.
    Bioorganic & medicinal chemistry, 2017, 11-01, Volume: 25, Issue:21

    Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles

2017
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.
    Bioorganic & medicinal chemistry, 2019, 09-15, Volume: 27, Issue:18

    Topics: Humans; Phthalazines

2019
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Antineoplastic Agents; Capecitabine; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prodrugs; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides; Treatment Outcome

2002
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides

2003
Current and ongoing trials with irinotecan in the United States.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides

2003
Novel opportunities in the treatment and prevention of scarring.
    Journal of cutaneous medicine and surgery, 2004, Volume: 8 Suppl 3

    Topics: Bleomycin; Botulinum Toxins, Type A; Celecoxib; Cicatrix; Fluorouracil; Humans; Immunosuppressive Agents; Laser Therapy; Neuromuscular Agents; Pyrazoles; Sulfonamides; Tacrolimus; Verapamil

2004
First-line therapeutic strategies in metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex

2008

Trials

27 trial(s) available for fluorouracil and celecoxib

ArticleYear
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
    Cancer, 2004, Jul-01, Volume: 101, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Celecoxib; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Treatment Outcome

2004
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Chemotherapy, Adjuvant; Cisplatin; Cyclooxygenase Inhibitors; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Pyrazoles; Radiotherapy, Adjuvant; Sulfonamides; Survival Analysis; Time Factors

2004
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
    Prostaglandins & other lipid mediators, 2005, Volume: 75, Issue:1-4

    Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Pyrazoles; Sulfonamides

2005
Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128.
    Gynecologic oncology, 2005, Volume: 97, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Celecoxib; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Gene Expression Profiling; Humans; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Pyrazoles; RNA; Sulfonamides; Uterine Cervical Neoplasms

2005
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pyrazoles; Sulfonamides; Treatment Outcome

2005
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome

2005
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    American journal of clinical oncology, 2006, Volume: 29, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Pain; Peripheral Nervous System Diseases; Pyrazoles; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome

2006
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome

2006
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2006, Volume: 60, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A

2006
Molecular responses of rectal cancer to preoperative chemoradiation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2006, Volume: 80, Issue:2

    Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Female; Fluorouracil; Humans; Immunohistochemistry; Interleukin-6; Ki-67 Antigen; Male; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Osteopontin; Preoperative Care; Prognosis; Pyrazoles; Rectal Neoplasms; Sulfonamides

2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Survival Rate; Treatment Outcome

2007
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
    Investigational new drugs, 2007, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis

2007
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
    International journal of radiation oncology, biology, physics, 2007, Jan-01, Volume: 67, Issue:1

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Cisplatin; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Pyrazoles; Radiotherapy Dosage; Sulfonamides; Uterine Cervical Neoplasms

2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-01, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides

2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure

2008
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
    International journal of radiation oncology, biology, physics, 2007, Sep-01, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Pyrazoles; Sulfonamides; Survival Rate; Treatment Failure; Uterine Cervical Neoplasms

2007
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
    Onkologie, 2007, Volume: 30, Issue:12

    Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Treatment Outcome

2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis

2008
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prodrugs; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate

2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides

2008
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Oncology, 2009, Volume: 76, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides

2009
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Cancer, 2009, Jun-15, Volume: 115, Issue:12

    Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate

2009
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009, Volume: 93, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Combined Modality Therapy; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Interleukin-6; Male; Middle Aged; Pyrazoles; Rectal Neoplasms; Sulfonamides

2009
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides

2010
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazoles; Sulfonamides

2012
Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
    The Journal of international medical research, 2011, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Demography; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome

2011
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids

2013

Other Studies

31 other study(ies) available for fluorouracil and celecoxib

ArticleYear
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Edema; Female; Male; Mice; Pyrroles

2011
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Male; Molecular Structure; Prostatic Neoplasms; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
    Bioorganic & medicinal chemistry, 2014, Aug-01, Volume: 22, Issue:15

    Topics: Binding Sites; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Female; HeLa Cells; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyrazoles; Quantitative Structure-Activity Relationship; Sulfonamides; Uterine Cervical Neoplasms

2014
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
    European journal of medicinal chemistry, 2016, Jan-27, Volume: 108

    Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Lipoxygenase Inhibitors; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship; Triazoles

2016
Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Antineoplastic Agents; Arachidonate 15-Lipoxygenase; Carbonic Anhydrases; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles

2020
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides

2002
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Hypoxia; Isoenzymes; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Peripheral Nervous System Diseases; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Syndrome

2002
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    International journal of oncology, 2003, Volume: 23, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Blotting, Western; Carcinoma; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Fluorouracil; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulindac; Time Factors; Vincristine

2003
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
    The Journal of investigative dermatology, 2004, Volume: 122, Issue:6

    Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Mice; Mice, Hairless; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Ultraviolet Rays

2004
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1

    Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohistochemistry; Intestinal Mucosa; Ki-67 Antigen; Lead; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides; Xenograft Model Antitumor Assays

2005
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2005, Volume: 59 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Pyrazoles; Sulfonamides

2005
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
    International journal of cancer, 2007, Aug-15, Volume: 121, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Screening Assays, Antitumor; Fluorouracil; Interferon-gamma; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A

2007
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
    World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; HT29 Cells; Humans; Pyrazoles; Sulfonamides

2007
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Fluorouracil; Humans; Lactones; Pyrazoles; Stomach Neoplasms; Sulfonamides; Sulfones

2007
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
    Journal of neuro-oncology, 2011, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult

2011
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
    International journal of radiation oncology, biology, physics, 2011, Aug-01, Volume: 80, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pyrazoles; Rectal Neoplasms; Sulfonamides; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Young Adult

2011
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2010, Volume: 10, Issue:5

    Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid Peroxides; Male; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Pyrazoles; Sulfonamides

2010
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:7

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays

2012
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
    World journal of surgical oncology, 2013, Jan-24, Volume: 11

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Celecoxib; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochromes c; Fluorouracil; HT29 Cells; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Injections, Subcutaneous; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays

2013
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2013, Volume: 35, Issue:4

    Topics: Animals; Capecitabine; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Transcription Factor RelA

2013
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
    International journal of oncology, 2014, Volume: 44, Issue:4

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Invasiveness; Orotate Phosphoribosyltransferase; Prostaglandins; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Sulfonamides

2014
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
    Oncology reports, 2014, Volume: 31, Issue:5

    Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Fluorouracil; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Microvessels; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazoles; Random Allocation; Sulfonamides; Vascular Endothelial Growth Factor A

2014
Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells.
    Molecular medicine reports, 2015, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Basic Helix-Loop-Helix Transcription Factors; Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Neoplasm Proteins; Octamer Transcription Factor-3; Pyrazoles; RNA, Messenger; Stomach Neoplasms; Sulfonamides

2015
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
    The Laryngoscope, 2017, Volume: 127, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Drug Interactions; Fluorouracil; Heterografts; Mice; Mice, Nude; Random Allocation; Reactive Oxygen Species; Reference Values; Skin Neoplasms; Statistics, Nonparametric; Survival Rate; Tumor Cells, Cultured

2017
Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Aniline Compounds; Brain Neoplasms; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Minor Histocompatibility Antigens; NF-kappa B; Nitriles; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Sulfones

2016
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
    Breast cancer research and treatment, 2022, Volume: 193, Issue:3

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Mastectomy

2022